|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARSI |
Gene summary for ARSI |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARSI | Gene ID | 340075 |
| Gene name | arylsulfatase family member I | |
| Gene Alias | ASI | |
| Cytomap | 5q32 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5FYB1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 340075 | ARSI | C04 | Human | Oral cavity | OSCC | 1.84e-03 | 3.82e-01 | 0.2633 |
| 340075 | ARSI | C21 | Human | Oral cavity | OSCC | 5.90e-28 | 9.08e-01 | 0.2678 |
| 340075 | ARSI | C30 | Human | Oral cavity | OSCC | 2.18e-49 | 1.86e+00 | 0.3055 |
| 340075 | ARSI | C38 | Human | Oral cavity | OSCC | 9.76e-03 | 4.71e-01 | 0.172 |
| 340075 | ARSI | C51 | Human | Oral cavity | OSCC | 2.53e-21 | 9.81e-01 | 0.2674 |
| 340075 | ARSI | C06 | Human | Oral cavity | OSCC | 3.14e-16 | 1.66e+00 | 0.2699 |
| 340075 | ARSI | SYSMH2 | Human | Oral cavity | OSCC | 2.21e-03 | 1.28e-01 | 0.2326 |
| 340075 | ARSI | SYSMH3 | Human | Oral cavity | OSCC | 6.64e-06 | 2.01e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARSI | SNV | Missense_Mutation | c.1534N>T | p.His512Tyr | p.H512Y | Q5FYB1 | protein_coding | deleterious(0.05) | benign(0.222) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARSI | SNV | Missense_Mutation | c.676C>G | p.Gln226Glu | p.Q226E | Q5FYB1 | protein_coding | tolerated(0.99) | benign(0.027) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ARSI | SNV | Missense_Mutation | c.676N>G | p.Gln226Glu | p.Q226E | Q5FYB1 | protein_coding | tolerated(0.99) | benign(0.027) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| ARSI | SNV | Missense_Mutation | c.1504G>A | p.Val502Ile | p.V502I | Q5FYB1 | protein_coding | tolerated(0.18) | possibly_damaging(0.777) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ARSI | SNV | Missense_Mutation | c.911C>T | p.Ser304Leu | p.S304L | Q5FYB1 | protein_coding | tolerated(0.12) | benign(0.021) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ARSI | SNV | Missense_Mutation | rs776520005 | c.940N>T | p.Arg314Cys | p.R314C | Q5FYB1 | protein_coding | tolerated(0.08) | benign(0.055) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ARSI | SNV | Missense_Mutation | rs775966190 | c.1673N>A | p.Arg558His | p.R558H | Q5FYB1 | protein_coding | deleterious_low_confidence(0.02) | benign(0.375) | TCGA-DM-A0X9-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARSI | SNV | Missense_Mutation | c.1100N>A | p.Gly367Glu | p.G367E | Q5FYB1 | protein_coding | tolerated(0.39) | benign(0.11) | TCGA-DM-A28C-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| ARSI | SNV | Missense_Mutation | c.313N>C | p.Tyr105His | p.Y105H | Q5FYB1 | protein_coding | tolerated(0.07) | benign(0.443) | TCGA-CI-6624-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ARSI | SNV | Missense_Mutation | c.637N>A | p.Ala213Thr | p.A213T | Q5FYB1 | protein_coding | tolerated(1) | benign(0.015) | TCGA-EF-5831-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |